<DOC>
	<DOCNO>NCT02851277</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ASP0892 intradermal intramuscular injection adult peanut allergy .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Immune Response Adults Allergic Peanut After Receiving Intradermal Intramuscular Administration ASP0892 ( ARA-LAMP-vax ) , Single Multivalent Peanut ( Ara h1 , h2 , h3 ) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Subject body mass index ( BMI ) ≥ 18 32 screening . Subject physiciandiagnosed peanut allergy history peanut allergy . Subjects history nonsevere anaphylaxis ( Grade ≤ 3 ) peanut ( include mild wheeze dyspnea without hypoxia ) enrol . Subject antiAra h2 IgE measure ImmunoCAP &gt; 0.35 kU/L . Subject positive SPT peanut change wheal diameter ≥ 3 mm compare negative control . Subject positive peanut doubleblinded placebocontrolled food challenge ( DBPCFC ) Screen 2 visit elicit dose ≤ 300 mg peanut protein ( ≤ 444 mg cumulative reactive dose [ CRD ] ) . Female subject must either : Be nonchild bear potential : postmenopausal ( define least 1 year without menses ) prior screen , document surgically sterile . Or , childbearing potential : Agree become pregnant study ; negative ( urine ) pregnancy test result screen day 1 ( predose ) ; , heterosexually active , agree consistently use 2 form highly effective birth control ( least one must barrier method ) start screen throughout study period . Female subject must agree breastfeed start screen throughout study period , 28 day final study drug administration . Female subject must donate ovum start screen throughout study period , 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control ( least one must barrier method ) start screen continue throughout study period , 90 day final study drug administration . Male subject must donate sperm start screen throughout study period , 90 day final study drug administration . Subject severe anaphylaxis peanut ( Grades 4 5 include dyspnea associate hypoxia , cyanosis , hypotension , neurological compromise ) per Grading FoodInduced Anaphylaxis According Severity Clinical Symptoms base historical clinical symptom . Subject develop Grade 4 5 reaction DBPCFC . Subject receive plan receive administration vaccine ( injectable Influenza vaccine ) within 28 day prior administration study vaccine time study . Subject receive specific immunotherapy allergy ( e.g. , epicutaneous immunotherapy [ EPIT ] , sublingual immunotherapy [ SLIT ] , subcutaneous immunotherapy [ SCIT ] , oral immunotherapy [ OIT ] ) past 12 month , currently , plan receive course study . Subject use follow drug ( ) prior dose study vaccine : Within 2 month prior study vaccine administration : Systemic ( inhale ) steroid , chemical mediatorisolation inhibitor , Th2 cytokine inhibitor , thromboxane A2 synthesis inhibitor , thromboxane A2 receptor antagonist , βblocker , angiotensinconverting enzyme inhibitor , and/or angiotensinreceptor blocker Within 3 month prior study vaccine administration : Biologics and/or immune modulators ( include antiTNFα antibody antiIgE monoclonal antibody ) Subject history allergic reaction anaphylactic shock , angioedema airway constriction hypotension cause food peanut and/or medical product ( include vaccine ) past . Subject 's laboratory test result screen prior study vaccine dose day 1 outside normal limit consider clinically significant . Subject antiLAMP antibody cutpoint Tier 1 assay confirm positive Tier 2 assay Screen 1 visit ( baseline ) . Subject positive test result hepatitis B surface ( HBs ) antigen , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antigen/ antibody . Subject immune disorder ( include autoimmune disease ) and/or diseases require immunosuppressive drug . Subject diagnose immunodeficiency past . Subject uncontrolled hypertension . Subject history cardiovascular disease , arrhythmia , chronic lung disease , active eosinophilic gastrointestinal disease , medical surgical condition place subject increase risk participation study . Subject complication medical history respiratory disease require medical treatment . Subject complication medical history malignant tumor . Subject mental condition schizophrenia , bipolar disorder , major depressive disorder , subject receive drug ( ) treatment dementia . Subject severe poorly control dermatitis atopic generalize eczema . Subject unable discontinue antihistamine 5 halflives prior dose , skin prick testing , oral food challenge procedure . Subject asthma mild intermittent asthma ( National Heart , Lung , Blood Institute [ NHLBI ] guideline ) FEV1 value &lt; 80 % and/or require chronic maintenance treatment ( i.e. , inhaled corticosteroid ) . Subject already receive vaccination LAMPvax ASP0892 . Subject receive investigational therapy within 35 day 5 half life whichever longer , prior screen . Subject employee Astellas Group vendor involve study . Subject condition make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Peanut Allergy</keyword>
	<keyword>ASP0892</keyword>
</DOC>